205 related articles for article (PubMed ID: 14709942)
21. Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment.
Govitrapong P; Mukda S; Turakitwanakan W; Dumrongphol H; Chindaduangratn C; Sanvarinda Y
Neurochem Int; 2002 Oct; 41(4):209-16. PubMed ID: 12106771
[TBL] [Abstract][Full Text] [Related]
22. Serotonin uptake and imipramine binding in the blood platelets of obsessive-compulsive disorder patients.
Bastani B; Arora RC; Meltzer HY
Biol Psychiatry; 1991 Jul; 30(2):131-9. PubMed ID: 1655071
[TBL] [Abstract][Full Text] [Related]
23. Binding of [3H]paroxetine to serotonin uptake sites and of [3H]lysergic acid diethylamide to 5-HT2A receptors in platelets from women with premenstrual dysphoric disorder during gonadotropin releasing hormone treatment.
Bixo M; Allard P; Bäckström T; Mjörndal T; Nyberg S; Spigset O; Sundström-Poromaa I
Psychoneuroendocrinology; 2001 Aug; 26(6):551-64. PubMed ID: 11403977
[TBL] [Abstract][Full Text] [Related]
24. Psychopathology and personality characteristics in relation to blood serotonin in Tourette's syndrome and obsessive-compulsive disorder.
Cath DC; Spinhoven P; Landman AD; van Kempen GM
J Psychopharmacol; 2001 Jun; 15(2):111-9. PubMed ID: 11448084
[TBL] [Abstract][Full Text] [Related]
25. Seasonal variations in the binding of [3H]paroxetine to the platelet serotonin transporter sites in African-American cocaine-dependent patients and healthy volunteers.
Patkar AA; Berrettini WH; Lundy A; Murray HW; Hill KP; Vergare MJ; Weinstein SP
Hum Psychopharmacol; 2003 Mar; 18(2):103-11. PubMed ID: 12590403
[TBL] [Abstract][Full Text] [Related]
26. Platelet 3H-imipramine binding sites in obsessive-compulsive behavior.
Kim SW; Dysken MW; Pandey GN; Davis JM
Biol Psychiatry; 1991 Sep; 30(5):467-74. PubMed ID: 1657222
[TBL] [Abstract][Full Text] [Related]
27. Platelet serotonin uptake and paroxetine binding among allelic genotypes of the serotonin transporter in alcoholics.
Javors MA; Seneviratne C; Roache JD; Ait-Daoud N; Bergeson SE; Walss-Bass MC; Akhtar FZ; Johnson BA
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jan; 29(1):7-13. PubMed ID: 15610939
[TBL] [Abstract][Full Text] [Related]
28. Forced swimming test and fluoxetine treatment: in vivo evidence that peripheral 5-HT in rat platelet-rich plasma mirrors cerebral extracellular 5-HT levels, whilst 5-HT in isolated platelets mirrors neuronal 5-HT changes.
Bianchi M; Moser C; Lazzarini C; Vecchiato E; Crespi F
Exp Brain Res; 2002 Mar; 143(2):191-7. PubMed ID: 11880895
[TBL] [Abstract][Full Text] [Related]
29. Initial platelet serotonin (5-HT) transport kinetics predict nortriptyline treatment outcome.
Rausch JL; Moeller FG; Johnson ME
J Clin Psychopharmacol; 2003 Apr; 23(2):138-44. PubMed ID: 12640215
[TBL] [Abstract][Full Text] [Related]
30. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder.
Humble M; Bejerot S; Bergqvist PB; Bengtsson F
Biol Psychiatry; 2001 Feb; 49(4):360-8. PubMed ID: 11239907
[TBL] [Abstract][Full Text] [Related]
31. Influence of menstrual cycle on platelet serotonin uptake site and serotonin2A receptor binding.
Wihlbäck AC; Sundström Poromaa I; Bixo M; Allard P; Mjörndal T; Spigset O
Psychoneuroendocrinology; 2004 Jul; 29(6):757-66. PubMed ID: 15110925
[TBL] [Abstract][Full Text] [Related]
32. Decreased lymphocyte 3H-paroxetine binding in obsessive-compulsive disorder.
Marazziti D; Baroni S; Masala I; Giannaccini G; Mungai F; Di Nasso E; Cassano GB
Neuropsychobiology; 2003; 47(3):128-30. PubMed ID: 12759554
[TBL] [Abstract][Full Text] [Related]
33. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
[TBL] [Abstract][Full Text] [Related]
34. Intact coding region of the serotonin transporter gene in obsessive-compulsive disorder.
Altemus M; Murphy DL; Greenberg B; Lesch KP
Am J Med Genet; 1996 Jul; 67(4):409-11. PubMed ID: 8837711
[TBL] [Abstract][Full Text] [Related]
35. Platelet paroxetine binding in major depressive disorder with and without comorbid obsessive-compulsive disorder.
Nelson EC; Sheline YI; Bardgett ME; Jackson JL; Csernansky JG
Psychiatry Res; 1995 Sep; 58(2):117-25. PubMed ID: 8570763
[TBL] [Abstract][Full Text] [Related]
36. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder.
Bengel D; Greenberg BD; Corá-Locatelli G; Altemus M; Heils A; Li Q; Murphy DL
Mol Psychiatry; 1999 Sep; 4(5):463-6. PubMed ID: 10523819
[TBL] [Abstract][Full Text] [Related]
37. No correlation between aggression and platelet (3)H-paroxetine binding in obsessive-compulsive disorder patients.
Marazziti D; Conti L; Pfanner C; Presta S; Rossi A; Gemignani A; Dell'Osso L; Cassano GB
Neuropsychobiology; 2001; 43(3):117-22. PubMed ID: 11287787
[TBL] [Abstract][Full Text] [Related]
38. Decrease in thalamic volumes of pediatric patients with obsessive-compulsive disorder who are taking paroxetine.
Gilbert AR; Moore GJ; Keshavan MS; Paulson LA; Narula V; Mac Master FP; Stewart CM; Rosenberg DR
Arch Gen Psychiatry; 2000 May; 57(5):449-56. PubMed ID: 10807485
[TBL] [Abstract][Full Text] [Related]
39. [Molecular pharmacogenetic studies of drug responses to obsessive-compulsive disorder and six functional genes].
Zhang L; Liu X; Li T; Yang Y; Hu X; Collier D
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Oct; 21(5):479-81. PubMed ID: 15476175
[TBL] [Abstract][Full Text] [Related]
40. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs.
Bismuth-Evenzal Y; Gonopolsky Y; Gurwitz D; Iancu I; Weizman A; Rehavi M
J Affect Disord; 2012 Jan; 136(1-2):99-103. PubMed ID: 21893349
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
